Literature DB >> 24375266

BRAF mutation status in papillary thyroid carcinoma: significance for surgical strategy.

P Miccoli1, F Basolo.   

Abstract

BACKGROUND: BRAF mutation is probably the only molecular marker acting as a risk factor that is available before surgery: for this reason, soon after it became quite widespread, it seemed an important tool as a guide towards an individualized surgical therapy in papillary thyroid carcinoma.
PURPOSE: Capsule invasion, multifocality, and lymph node involvement are the most important parameters influencing the choice of surgical strategy in front of small papillary cancers and, in more detail, of micro papillary carcinomas. The relationship between these parameters and the BRAF mutation are closely examined through the more recent literature. Capsular invasion seems to show the strongest correlation with the mutation and this has important correlations, thus suggesting that a more aggressive local surgery might be advisable, whereas the correlation between the mutation and lymph node involvement would be weaker, at least according to the most recent studies.
CONCLUSIONS: The personalization of surgical therapy, today, seems easier to achieve thanks to molecular testing. In particular, an important result could be in the short term reduction in the number of completion thyroidectomies following simple lobectomies. Also, post operative radioactivated iodine therapies should be more carefully evaluated and tailored according to BRAF status. A possible flow chart for the decision of the therapeutic approach is proposed in accordance to the results of the literature.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24375266     DOI: 10.1007/s00423-013-1153-7

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  19 in total

1.  Impact of combined prophylactic unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid microcarcinoma.

Authors:  Sang Min Hyun; Hyoung Young Song; Sang Yoon Kim; Soon Yuhl Nam; Jong-Lyel Roh; Myung Woul Han; Seung-Ho Choi
Journal:  Ann Surg Oncol       Date:  2011-08-12       Impact factor: 5.344

2.  Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy.

Authors:  Paolo Miccoli; Aldo Pinchera; Gabriele Materazzi; Agnese Biagini; Piero Berti; Pinuccia Faviana; Eleonora Molinaro; David Viola; Rossella Elisei
Journal:  J Clin Endocrinol Metab       Date:  2009-02-17       Impact factor: 5.958

3.  Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.

Authors:  Linwah Yip; Marina N Nikiforova; Sally E Carty; John H Yim; Michael T Stang; Mitchell J Tublin; Shane O Lebeau; Steven P Hodak; Jennifer B Ogilvie; Yuri E Nikiforov
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

Review 4.  Current status of robotic thyroidectomy and neck dissection using a gasless transaxillary approach.

Authors:  Jandee Lee; Woong Y Chung
Journal:  Curr Opin Oncol       Date:  2012-01       Impact factor: 3.645

5.  The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.

Authors:  Tae Yong Kim; Won Bae Kim; Ja Young Song; Yoon Soo Rhee; Gyungyub Gong; Yong Mee Cho; Sang Yoon Kim; Seong Chul Kim; Suck Joon Hong; Young Kee Shong
Journal:  Clin Endocrinol (Oxf)       Date:  2005-11       Impact factor: 3.478

6.  Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.

Authors:  Fulvio Basolo; Liborio Torregrossa; Riccardo Giannini; Mario Miccoli; Cristiana Lupi; Elisa Sensi; Piero Berti; Rossella Elisei; Paolo Vitti; Angelo Baggiani; Paolo Miccoli
Journal:  J Clin Endocrinol Metab       Date:  2010-07-14       Impact factor: 5.958

7.  Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.

Authors:  Greta Gandolfi; Valentina Sancisi; Federica Torricelli; Moira Ragazzi; Andrea Frasoldati; Simonetta Piana; Alessia Ciarrocchi
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

8.  Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.

Authors:  Ali S Alzahrani; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2013-01-21       Impact factor: 5.678

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  Presence of BRAF V600E in very early stages of papillary thyroid carcinoma.

Authors:  Clara Ugolini; Riccardo Giannini; Cristiana Lupi; Giuliana Salvatore; Paolo Miccoli; Agnese Proietti; Rossella Elisei; Massimo Santoro; Fulvio Basolo
Journal:  Thyroid       Date:  2007-05       Impact factor: 6.568

View more
  6 in total

1.  Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population.

Authors:  Ryan J Gertz; Yuri Nikiforov; William Rehrauer; Lee McDaniel; Ricardo V Lloyd
Journal:  Arch Pathol Lab Med       Date:  2016-02       Impact factor: 5.534

Review 2.  Tailored surgery according to molecular analysis in differentiated thyroid carcinomas.

Authors:  Paolo Miccoli; Gabriele Materazzi; Elisabetta Macerola; Sohail Bakkar
Journal:  Gland Surg       Date:  2018-08

3.  Associations of BRAF V600E, clinical pathology and imaging factors with the recurrence rate of papillary thyroid microcarcinoma.

Authors:  Kun Huang; Ningning Gao; Donglin Bian; Qixi Zhai; Puxu Yang; Yunfei Zhang
Journal:  Exp Ther Med       Date:  2020-10-22       Impact factor: 2.447

4.  Application of molecular diagnostics to the evaluation of the surgical approach to thyroid cancer.

Authors:  Paolo Miccoli
Journal:  Curr Genomics       Date:  2014-06       Impact factor: 2.236

5.  Correlation between Ultrasonographic Appearance of Papillary Thyroid Microcarcinoma and BRAF V600E Mutation.

Authors:  Songnian Liang; Kun Huang
Journal:  J Oncol       Date:  2022-03-21       Impact factor: 4.375

6.  V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients.

Authors:  Aihemaijiang Kuerbanjiang; Maimaitiyiming Maimaituerxun; Yanjun Zhang; Yiliang Li; Gang Cui; Aibaidula Abuduhabaier; Abuduwaili Aierken; Buya Miranbieke; Meilikezati Anzaer; Yusufu Maimaiti
Journal:  BMC Gastroenterol       Date:  2021-02-23       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.